nVerses Capital LLC Buys 400 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

nVerses Capital LLC lifted its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 18.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,600 shares of the company’s stock after purchasing an additional 400 shares during the quarter. nVerses Capital LLC’s holdings in Amphastar Pharmaceuticals were worth $126,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Silvercrest Asset Management Group LLC raised its stake in shares of Amphastar Pharmaceuticals by 35.1% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after purchasing an additional 29,182 shares during the period. Allspring Global Investments Holdings LLC grew its position in Amphastar Pharmaceuticals by 61.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 64,564 shares of the company’s stock worth $2,835,000 after buying an additional 24,678 shares in the last quarter. Intech Investment Management LLC purchased a new position in Amphastar Pharmaceuticals during the second quarter worth about $426,000. Nordea Investment Management AB grew its position in Amphastar Pharmaceuticals by 0.4% during the first quarter. Nordea Investment Management AB now owns 333,014 shares of the company’s stock worth $14,802,000 after buying an additional 1,209 shares in the last quarter. Finally, Granite Investment Partners LLC grew its position in Amphastar Pharmaceuticals by 12.7% during the second quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after buying an additional 44,744 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several recent analyst reports. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $63.00.

Amphastar Pharmaceuticals Price Performance

AMPH opened at $50.84 on Monday. The stock has a 50-day moving average price of $47.27 and a 200-day moving average price of $43.19. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The company has a current ratio of 3.52, a quick ratio of 2.63 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $2.49 billion, a P/E ratio of 17.59, a PEG ratio of 0.88 and a beta of 0.83.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The firm had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. Equities analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current fiscal year.

Insider Transactions at Amphastar Pharmaceuticals

In related news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the sale, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 10,282 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total transaction of $454,772.86. Following the completion of the transaction, the chief financial officer now owns 94,103 shares of the company’s stock, valued at $4,162,175.69. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Rong Zhou sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the transaction, the executive vice president now directly owns 118,388 shares of the company’s stock, valued at $5,724,059.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 34,383 shares of company stock worth $1,524,123. 27.10% of the stock is currently owned by corporate insiders.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.